Drugs /

blu-945

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for blu-945

Blu-945 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating blu-945, 1 is phase 1/phase 2 (1 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for blu-945 clinical trials.

Non-small cell lung carcinoma is the most common disease being investigated in blu-945 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Blu-945
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating blu-945 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
blu 945, blu945

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.